Seres Therapeutics (MCRB) Other Non-Current Liabilities (2014 - 2026)

Seres Therapeutics has reported Other Non-Current Liabilities for 11 years, with the latest figure at $2.1 million in Q1 2026.

• Quarterly Other Non-Current Liabilities rose 12.98% year-over-year to $2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 million (up 12.98% YoY) and the FY2025 annual result came in at $2.1 million, up 13.0% from the prior year.
• Other Non-Current Liabilities grew to $2.1 million in Q1 2026 per MCRB's latest filing, from $2.1 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $3.9 million in Q1 2022 and troughed at $130000.0 in Q1 2024.
• A 5-year average of $1.7 million and a median of $1.7 million in 2023 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities plunged 91.25% in 2024, then soared 1357.69% in 2025.
• Over 5 years, Other Non-Current Liabilities stood at $1.4 million in 2022, then grew by 12.9% to $1.6 million in 2023, then advanced by 12.9% to $1.8 million in 2024, then advanced by 13.0% to $2.1 million in 2025, then rose by 3.08% to $2.1 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $2.1 million, $2.1 million, and $2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.